A clinical trial’s success depends on collaboration between two organizations with different responsibilities and, often, different systems: the sponsor, who owns the trial and its regulatory obligations, and the CRO, whose specialized expertise executes much of the work day to day. How that collaboration is structured has changed over time, but one thing about it has not: the sponsor’s oversight responsibility does not move just because the work does.
From Full Outsourcing to Shared Ownership
Sponsors have traditionally relied on CROs to run large portions of trial execution end to end, an arrangement built around handing off defined scopes of work. A different model has been gaining ground alongside that one: sponsors bringing certain functions in-house or under closer direct management, while still relying on CRO expertise for others. Neither model is inherently better; they represent different choices about where day-to-day operational control sits. What matters more than which model a sponsor chooses is what stays constant regardless of the choice.
The Oversight Responsibility That Doesn’t Transfer
Under GCP and ICH E6(R3) guidelines, a sponsor’s duty of oversight is non-delegable: work can be assigned to a CRO, but accountability for that work cannot be. That single fact is what makes the choice between collaboration models an operational question, not a governance one. Whichever way a sponsor divides the work, it still needs visibility into what the CRO is doing, on what timeline, and with what documentation, because that visibility is what the sponsor’s own oversight duty depends on regardless of who is doing the underlying task.
Where Collaboration Actually Breaks Down
The friction in sponsor-CRO collaboration rarely shows up in the clinical work itself; both organizations are typically competent at what they were engaged to do. It shows up at the boundary between them: a document version that diverges between the sponsor’s and the CRO’s copies, a decision made on one side that reaches the other late or informally, a protocol change that one organization considers final while the other is still reviewing it. That boundary is organizational, not technical, and it exists no matter which collaboration model a sponsor has chosen for a given program.
A Shared Layer, Not a Shared System
Bridging that boundary does not require the sponsor and the CRO to run the same systems of record; each organization has its own, and neither should have to give that up. What it requires is a shared, governed space for the work that has to happen across the boundary: reviewing a protocol change together, documenting a joint decision, tracking a handoff so both sides can confirm it actually happened when it was supposed to.
An Enterprise Clinical Execution Platform exists for exactly that space, standardizing the collaboration between sponsor and CRO without asking either one to replace what already works internally. Neither organization has to change how it runs its own systems for the boundary between them to become more reliable.
Collaboration Models Will Keep Changing. Oversight Will Not.
Whatever balance of outsourcing and shared ownership a sponsor and a CRO settle on for a given program, the sponsor’s obligation to see and stand behind the work does not shrink to match. A sponsor that treats the boundary between organizations as deliberately as it treats the boundary between systems is the sponsor whose oversight holds up regardless of which collaboration model the industry favors next.
That durability, not any particular staffing arrangement, is what actually shapes how well a trial is run over its full life cycle. Models for dividing labor between sponsors and CROs will keep evolving as the industry finds new ways to combine specialized expertise with direct control. The oversight obligation sitting underneath all of them is the one constant a sponsor can plan around, whichever model it chooses next.
Building the Boundary In From the Start
Sponsors and CROs that treat this coordination layer as something to establish at the outset of a relationship, rather than something to patch together once friction has already surfaced, tend to have an easier time adjusting when the division of labor changes mid-program, as it often does when a sponsor shifts functions in-house or expands what it delegates to a CRO partway through a trial. A governed space for cross-boundary work that already exists absorbs that kind of change far more easily than one that has to be invented at the moment the model shifts.
The alternative, discovering the coordination gap only after a document has diverged or a decision has gone unrecorded, means resolving the problem under exactly the conditions least suited to it: an active trial, a live sponsor-CRO relationship, and a boundary that has already produced the kind of confusion both organizations were trying to avoid. Establishing the shared layer early is not just tidier. It is the difference between a boundary that bends when the model changes and one that breaks.
What This Means for Choosing a CRO Partner
A sponsor evaluating a CRO relationship, whether at the start of a program or in the middle of restructuring one, gains more from asking how visibility and documentation work across the sponsor-CRO boundary than from asking which collaboration model the CRO prefers. A CRO that can describe, concretely, how a sponsor will see the status of delegated work in progress, and how a joint decision gets recorded so both organizations have the same account of it, is describing a boundary built to hold up under scrutiny. A CRO that can only describe its own internal process, however mature, has not yet answered the question a sponsor’s non-delegable oversight duty actually depends on.